

Company Announcement
ASX: HPC
DATE: 19/03/2025

Capital Raising – Amended Rights Issue Timetable

Hydration solutions company **The Hydration Pharmaceuticals Company Limited (ASX: HPC)** (“Hydralyte USA” or “the Company”) refers to the capital raising announced on 18 March 2025 comprising:

- a placement of 65,000,000 fully paid ordinary shares (“Shares”) at the Offer Price of \$0.01 per Share to raise \$650,000 (“Placement”); and
- a pro rata entitlement offer (“Rights Issue”), which will seek to raise up to an additional ~\$610,000 through the offer to eligible shareholders of 1 new Share for every 5 existing Shares held on the Record Date, at the Offer Price.

Further details regarding the capital raising are provided in the Company’s announcements of 18 March 2025.

Updated Rights Issue Timetable

Hydralyte USA advises that the indicative timetable for the Rights Issue component of the capital raising has been varied as set out in the table below.

The Company confirms that there is no change to the timetable for the Placement and the capital raising is otherwise unaffected.

Event	New Date	Old Date
Appendix 3B lodged with ASX	Wednesday, 19 March 2025	Tuesday, 18 March 2025
Record Date	Monday, 24 March 2025 (7.00pm AEDT)	Friday, 21 March 2025, 7.00pm AEDT
Settlement of the Placement Company lodges Appendix 2A	Tuesday, 25 March 2025 (unchanged)	Tuesday, 25 March 2025
New Shares issued under the Placement Company lodges notice under section 708A	Wednesday, 26 March 2025 (unchanged)	Wednesday, 26 March 2025
Opening Date of the Rights Issue	Thursday, 27 March 2025	Wednesday, 26 March 2025
Company makes Offer Booklet available to Eligible Shareholders	Thursday, 27 March 2025	Wednesday, 26 March 2025
Closing Date of the Rights Issue	Friday, 11 April 2025, 5.00pm AEST (unchanged)	Friday, 11 April 2025, 5:00pm AEST
Announcement of results of the Rights Issue	Wednesday, 16 April 2025 (unchanged)	Wednesday, 16 April 2025
Settlement of the Rights Issue	Thursday, 17 April 2025 (unchanged)	Thursday, 17 April 2025
Issue of Shares under the Rights Issue Company lodges Appendix 2A	Tuesday, 22 April 2025 (unchanged)	Tuesday, 22 April 2025
Trading of Shares	Wednesday, 23 April 2025 (unchanged)	Wednesday, 23 April 2025

Event	New Date	Old Date
Despatch of holding statements for the Shares	Wednesday, 23 April 2025 (unchanged)	Wednesday, 23 April 2025

ENDS

This announcement was authorised for release by the Board of HydraLyte USA.

For further information:

Investors/Media

Henry Jordan

Six Degrees Investor Relations

0431 271 538

henry.jordan@sdir.com.au

Forward Looking Statements

This ASX release includes certain forward-looking statements that are based on information and assumptions known to date and are subject to various risks and uncertainties. Forward-looking statements are based on:

assumptions regarding the Company's financial position, business strategies, plans and objectives of management for future operations and development and the environment in which the Company will operate; and current views, expectations, and beliefs as at the date they are expressed, and which are subject to various risks and uncertainties.

Actual results, performance or achievements could be significantly different from those expressed in, or implied by, these forward-looking statements. Such forward-looking statements are not guaranteeing of future performance and involve known and unknown risks, uncertainties, and other factors, many of which are beyond the control of HydraLyte USA. These factors may cause actual results to differ materially from those expressed in the statements contained in this announcement.

The Company disclaims any responsibility for the accuracy or completeness of any forward-looking statement. The Company disclaims any responsibility to update or revise any forward-looking statements to reflect any change in the Company's financial condition, status or affairs or any change in the events, conditions, or circumstances on which a statement is based, except as required by law. The projections or forecasts included in this announcement have not been audited, examined, or otherwise reviewed by the independent auditors of the Company.

You must not place undue reliance on these forward-looking statements.